v3.26.1
Acquisition of Faeth and Pipe Issuance - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Feb. 17, 2026
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Business Combination [Line Items]              
Preferred stock, par value   $ 0.0001     $ 0.0001   $ 0.0001
Common stock, par value   $ 0.0001     $ 0.0001   $ 0.0001
Percentage owned prior to the acquisition 4.90%            
Exercise of options into common stock, shares         134,185    
Research and development expenses for tax gross up payments related to vesting options         $ 9,100    
General and administrative expenses   $ 9,205   $ 2,673 28,918 $ 6,222  
General and administrative expenses for tax gross up payments related to vesting options         6,500    
Prepaid Expenses         $ 11,400    
Common Stock              
Business Combination [Line Items]              
Exercise of options into common stock, shares   57,042 77,143        
Series B Preferred Stock              
Business Combination [Line Items]              
Shares issued 14,440.395            
Preferred stock, par value $ 0.0001            
Remaining Unconverted shares   501.899     501.899    
Share price $ 13,850            
Preferred stock convert to common stock 1,000       1,000    
Assumed Options              
Business Combination [Line Items]              
General and administrative expenses         $ 700    
Maximum | Assumed Options              
Business Combination [Line Items]              
Research and development expenses         100    
Private Placement              
Business Combination [Line Items]              
Gross proceeds $ 200,000            
Percentage owned prior to the acquisition 54.50%            
Private Placement | Series B Preferred Stock              
Business Combination [Line Items]              
Shares issued 14,440.395            
Faeth Therapeutics LLC              
Business Combination [Line Items]              
Percentage owned prior to the acquisition 40.60%            
Employees vesting options 4,273,182            
Exercise of options into common stock, shares 6,338,670            
Research and development expenses related to accelerated vesting options $ 4,800       4,800    
General and administrative expenses related to accelerated vesting options $ 6,200       $ 6,200    
Accelerated vesting options         4,273,182    
Faeth Therapeutics LLC | Common Stock              
Business Combination [Line Items]              
Shares issued 10,497,098            
Common stock, par value $ 0.0001            
Common stock converted in to warrants to purchase common stock 2,102            
Common stock converted in to options to purchase common stock 252,210            
Faeth Therapeutics LLC | Series B Preferred Stock              
Business Combination [Line Items]              
Shares issued 10,497.098            
Preferred stock, par value $ 0.0001            
Common stock converted in to warrants to purchase common stock 2.102            
Faeth HoldCo              
Business Combination [Line Items]              
Tax liabilities of exercise options $ 15,600            
Faeth Therapeutics              
Business Combination [Line Items]              
Date of acquisition Feb. 17, 2026            
Total consideration transferred $ 145,836            
Faeth Therapeutics | Series B Preferred Stock              
Business Combination [Line Items]              
Total consideration transferred 145,384            
Faeth Therapeutics | Assumed Options              
Business Combination [Line Items]              
Total consideration transferred $ 452